Awareness and Knowledge Among Internal Medicine House-Staff for Dose Adjustment of Cardiovascular Drugs in Chronic Kidney Disease
AbstractIntroductionPatients with chronic kidney disease (CKD) are vulnerable to adverse-drug events from cardiovascular drugs.AimTo evaluate  awareness and knowledge for appropriate dose adjustment of cardiovascular drugs in CKD patients among Internal Medicine house-staff (IMHS).MethodsCross-sectional convenience sample survey in Fall 2015 among 341 IMHS from multiple academic institutions in the suburban New York City metropolitan area. Awareness was whether drug dose adjustment was needed. Knowledge was correct GFR level for drug dose adjustment. Multivariate logistic regression was conducted.ResultsWe found overa...
Source: High Blood Pressure and Cardiovascular Prevention - February 24, 2021 Category: Cardiology Source Type: research

Diabetes-induced auditory complications: are they preventable? a comprehensive review of interventions
AbstractDiabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels, which, over time, lead to major chronic complications in various organs of the body. A growing body of research suggests that diabetes could also result in degenerative changes in the auditory system. To date, several attempts have been made to prevent and reduce diabetes-induced auditory complications. Such attempts have generally focused on disease modifying as well as other pharmacological treatments involving several herbal and non-herbal agents such as vitamins C and E, rutin, resveratrol, coffee, trigonelline,Dio...
Source: European Archives of Oto-Rhino-Laryngology - February 8, 2021 Category: ENT & OMF Source Type: research

Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review
BackgroundPARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However, patients in clinical practice may differ in their characteristics and overall risk compared with patients in clinical trials, and additional outcomes can be observed in real world (RW). Hence, a systematic review was conducted to identify and describe RW data on sac/val.MethodsRW studies evaluating the effects of sac/val in adult patients with HFrEF with a sample size ≥100 were identified via MEDLINE® and Embase® from 2015 to January 2020....
Source: International Journal of Cardiology - February 2, 2021 Category: Cardiology Authors: Clare Proudfoot, Rachel Studer, Tanvi Rajput, Ramandeep Jindal, Rumjhum Agrawal, Stefano Corda, Michele Senni Source Type: research

Reverse Cardiac Remodeling and ARNI Therapy
AbstractPurpose of ReviewTo review reverse cardiac remodeling and guideline-directed medical and device therapy (GDMT) within the context of recent data on combined angiotensin receptor/neprilysin inhibitor (ARNI) therapy.Recent FindingsPreliminary data suggested that ARNI therapy led to significant reversal of deleterious cardiac remodeling. More definitive data regarding impact of ARNI therapy on remodeling parameters are now available from two prospective trials, PROVE-HF (Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure) and EVALUATE-...
Source: Current Heart Failure Reports - January 22, 2021 Category: Cardiology Source Type: research

Is Current Drug Therapy for Heart Failure Sufficient to Control Heart Rate of Patients?
Resumo Fundamento Estudos revelam que pacientes com insufici ência cardíaca (IC) e frequência cardíaca (FC)70. Entretanto, muitos pacientes com IC mant êm FC elevada. Objetivo Avaliar se os pacientes acompanhados em ambulatório de cardiologia têm sua FC controlada e como estava a prescrição dos medicamentos que reduzem a mortalidade na IC. Métodos Foram analisados de forma consecutiva pacientes que passaram em consulta e que já acompanha vam em ambulatório de cardiologia, idade> 18 anos e com diagn óstico de IC e fração ...
Source: Arquivos Brasileiros de Cardiologia - January 18, 2021 Category: Cardiology Source Type: research

Heart Rate Control in Heart Failure
Resumo Fundamento Estudos revelam que pacientes com insufici ência cardíaca (IC) e frequência cardíaca (FC)70. Entretanto, muitos pacientes com IC mant êm FC elevada. Objetivo Avaliar se os pacientes acompanhados em ambulatório de cardiologia têm sua FC controlada e como estava a prescrição dos medicamentos que reduzem a mortalidade na IC. Métodos Foram analisados de forma consecutiva pacientes que passaram em consulta e que já acompanha vam em ambulatório de cardiologia, idade> 18 anos e com diagn óstico de IC e fração ...
Source: Arquivos Brasileiros de Cardiologia - January 18, 2021 Category: Cardiology Source Type: research

Inhibitors of angiotensin I converting enzyme potentiate fibromyalgia-like pain symptoms via kinin receptors in mice.
ra SM Abstract Fibromyalgia is a potentially disabling chronic disease, characterized by widespread pain and a range of comorbidities such as hypertension. Among the mechanisms involved in fibromyalgia-like pain symptoms are kinins and their B1 and B2 receptors. Moreover, angiotensin I converting enzyme (ACE) inhibitors, commonly used as antihypertensive drugs, can enhance pain by blocking the degradation of peptides such as substance P and bradykinin, besides enhancing kinin receptors signalling. We investigated the effect of ACE inhibitors on reserpine-induced fibromyalgia-like pain symptoms and the involvement ...
Source: European Journal of Pharmacology - January 18, 2021 Category: Drugs & Pharmacology Authors: Brusco I, Justino AB, Silva CR, Scussel R, Machado-de-Ávila RA, Oliveira SM Tags: Eur J Pharmacol Source Type: research

Role of glomerular filtration rate ‐modifying drugs in the development of anticoagulant‐related nephropathy
ConclusionsGFR does not play a significant role in the dabigatran ‐induced acute kidney injury in 5/6 nephrectomy model in rats. Based in these data, modification of GFR in patients with ARN is not warranted. (Source: Physiological Reports)
Source: Physiological Reports - January 11, 2021 Category: Physiology Authors: Ajay K. Medipally, Min Xiao, Brad H. Rovin, Anjali A. Satoskar, Iouri Ivanov, Shahzeb Qaisar, Sergey V. Brodsky Tags: ORIGINAL RESEARCH Source Type: research

Association of Proteinuria with Urinary Concentration Defect in Puromycin Aminonucleoside Nephrosis.
Conclusion: In PAN, glomerular proteinuria was associated with tubulointerstitial injury and water diuresis. Downregulation of aquaporin-1 and NKCC2 can impair countercurrent multiplication and cause a urinary concentration defect in PAN. PMID: 33408745 [PubMed] (Source: Electrolyte and Blood Pressure)
Source: Electrolyte and Blood Pressure - January 9, 2021 Category: Internal Medicine Tags: Electrolyte Blood Press Source Type: research

Characteristics of Patients with Hypertension at a Nicaraguan Clinic
CONCLUSIONS: Hypertension is common in this clinic population and most commonly treated with angiotension-receptor blockers or angiotensin converting enzyme inhibitors.PMID:33416694 | DOI:10.1353/hpu.2020.0094 (Source: Journal of Health Care for the Poor and Underserved)
Source: Journal of Health Care for the Poor and Underserved - January 8, 2021 Category: International Medicine & Public Health Authors: Jennifer S Lee Mark Humphrey Morgan Adams Myriam Torres Timothy N Crawford Jeff Hall Source Type: research

Characteristics of Patients with Hypertension at a Nicaraguan Clinic
CONCLUSIONS: Hypertension is common in this clinic population and most commonly treated with angiotension-receptor blockers or angiotensin converting enzyme inhibitors.PMID:33416694 | DOI:10.1353/hpu.2020.0094 (Source: Journal of Health Care for the Poor and Underserved)
Source: Journal of Health Care for the Poor and Underserved - January 8, 2021 Category: International Medicine & Public Health Authors: Jennifer S Lee Mark Humphrey Morgan Adams Myriam Torres Timothy N Crawford Jeff Hall Source Type: research

Characteristics of Patients with Hypertension at a Nicaraguan Clinic
CONCLUSIONS: Hypertension is common in this clinic population and most commonly treated with angiotension-receptor blockers or angiotensin converting enzyme inhibitors.PMID:33416694 | DOI:10.1353/hpu.2020.0094 (Source: Journal of Health Care for the Poor and Underserved)
Source: Journal of Health Care for the Poor and Underserved - January 8, 2021 Category: International Medicine & Public Health Authors: Jennifer S Lee Mark Humphrey Morgan Adams Myriam Torres Timothy N Crawford Jeff Hall Source Type: research

Characteristics of Patients with Hypertension at a Nicaraguan Clinic
CONCLUSIONS: Hypertension is common in this clinic population and most commonly treated with angiotension-receptor blockers or angiotensin converting enzyme inhibitors.PMID:33416694 | DOI:10.1353/hpu.2020.0094 (Source: Journal of Health Care for the Poor and Underserved)
Source: Journal of Health Care for the Poor and Underserved - January 8, 2021 Category: International Medicine & Public Health Authors: Jennifer S Lee Mark Humphrey Morgan Adams Myriam Torres Timothy N Crawford Jeff Hall Source Type: research

Characteristics of Patients with Hypertension at a Nicaraguan Clinic
CONCLUSIONS: Hypertension is common in this clinic population and most commonly treated with angiotension-receptor blockers or angiotensin converting enzyme inhibitors.PMID:33416694 | DOI:10.1353/hpu.2020.0094 (Source: Journal of Health Care for the Poor and Underserved)
Source: Journal of Health Care for the Poor and Underserved - January 8, 2021 Category: International Medicine & Public Health Authors: Jennifer S Lee Mark Humphrey Morgan Adams Myriam Torres Timothy N Crawford Jeff Hall Source Type: research

Characteristics of Patients with Hypertension at a Nicaraguan Clinic
CONCLUSIONS: Hypertension is common in this clinic population and most commonly treated with angiotension-receptor blockers or angiotensin converting enzyme inhibitors.PMID:33416694 | DOI:10.1353/hpu.2020.0094 (Source: Journal of Health Care for the Poor and Underserved)
Source: Journal of Health Care for the Poor and Underserved - January 8, 2021 Category: International Medicine & Public Health Authors: Jennifer S Lee Mark Humphrey Morgan Adams Myriam Torres Timothy N Crawford Jeff Hall Source Type: research

Characteristics of Patients with Hypertension at a Nicaraguan Clinic
CONCLUSIONS: Hypertension is common in this clinic population and most commonly treated with angiotension-receptor blockers or angiotensin converting enzyme inhibitors.PMID:33416694 | DOI:10.1353/hpu.2020.0094 (Source: Journal of Health Care for the Poor and Underserved)
Source: Journal of Health Care for the Poor and Underserved - January 8, 2021 Category: International Medicine & Public Health Authors: Jennifer S Lee Mark Humphrey Morgan Adams Myriam Torres Timothy N Crawford Jeff Hall Source Type: research

Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.
CONCLUSIONS: Enalapril and etonogestrel were responsible for a significant proportion of ADRs reported to this provincial programme. Future work should include quantification of preventability aspects to better inform gaps in healthcare worker knowledge that can be addressed in order to improve patient care. PMID: 33403970 [PubMed - in process] (Source: South African Medical Journal)
Source: South African Medical Journal - January 7, 2021 Category: African Health Tags: S Afr Med J Source Type: research

Life-threatening airway obstruction caused by angioedema in a morbidly obese postoperative patient: a case report.
CONCLUSIONS: Angioedema induced by angiotensin-converting enzyme (ACE) inhibitors is rare; however, once it occurs, it can be potentially life threatening, especially for patients with possible difficult airway. Considering the risk-benefit ratio, we must be careful in administering ACE inhibitor therapy in morbidly obese patients. PMID: 33398469 [PubMed] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - January 4, 2021 Category: Cancer & Oncology Authors: Konda M, Inoue S, Naito Y, Egawa J, Kawaguchi M Tags: JA Clin Rep Source Type: research

Hospital Outpatient Visits Associated With Medication-Related Problems in Thailand: A Multicenter Prospective Observational Study
Conclusions Outpatient department visits associated with MRPs, particularly in nonelective patients, were preventable. Effective strategies are needed for reducing visits to hospital OPD associated with preventable MRPs. (Source: Journal of Patient Safety)
Source: Journal of Patient Safety - January 1, 2021 Category: Health Management Tags: Original Articles Source Type: research

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
CONCLUSION: Results support the use of sacubitril/valsartan in Indian patients with chronic HF with reduced ejection fraction with treatment benefits similar to global PARADIGM-HF cohort.PMID:33357641 | PMC:PMC7772612 | DOI:10.1016/j.ihj.2020.09.016 (Source: Indian Heart J)
Source: Indian Heart J - December 28, 2020 Category: Cardiology Authors: Anil Ranjeetmal Jain Rakesh Kumar Aggarwal Nanyam Srinivas Rao Gauri Billa Shankar Kumar Source Type: research

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
CONCLUSION: Results support the use of sacubitril/valsartan in Indian patients with chronic HF with reduced ejection fraction with treatment benefits similar to global PARADIGM-HF cohort.PMID:33357641 | PMC:PMC7772612 | DOI:10.1016/j.ihj.2020.09.016 (Source: Indian Heart J)
Source: Indian Heart J - December 28, 2020 Category: Cardiology Authors: Anil Ranjeetmal Jain Rakesh Kumar Aggarwal Nanyam Srinivas Rao Gauri Billa Shankar Kumar Source Type: research

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
CONCLUSION: Results support the use of sacubitril/valsartan in Indian patients with chronic HF with reduced ejection fraction with treatment benefits similar to global PARADIGM-HF cohort.PMID:33357641 | PMC:PMC7772612 | DOI:10.1016/j.ihj.2020.09.016 (Source: Indian Heart J)
Source: Indian Heart J - December 28, 2020 Category: Cardiology Authors: Anil Ranjeetmal Jain Rakesh Kumar Aggarwal Nanyam Srinivas Rao Gauri Billa Shankar Kumar Source Type: research

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
CONCLUSION: Results support the use of sacubitril/valsartan in Indian patients with chronic HF with reduced ejection fraction with treatment benefits similar to global PARADIGM-HF cohort.PMID:33357641 | PMC:PMC7772612 | DOI:10.1016/j.ihj.2020.09.016 (Source: Indian Heart J)
Source: Indian Heart J - December 28, 2020 Category: Cardiology Authors: Anil Ranjeetmal Jain Rakesh Kumar Aggarwal Nanyam Srinivas Rao Gauri Billa Shankar Kumar Source Type: research

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
CONCLUSION: Results support the use of sacubitril/valsartan in Indian patients with chronic HF with reduced ejection fraction with treatment benefits similar to global PARADIGM-HF cohort.PMID:33357641 | PMC:PMC7772612 | DOI:10.1016/j.ihj.2020.09.016 (Source: Indian Heart J)
Source: Indian Heart J - December 28, 2020 Category: Cardiology Authors: Anil Ranjeetmal Jain Rakesh Kumar Aggarwal Nanyam Srinivas Rao Gauri Billa Shankar Kumar Source Type: research

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
CONCLUSION: Results support the use of sacubitril/valsartan in Indian patients with chronic HF with reduced ejection fraction with treatment benefits similar to global PARADIGM-HF cohort.PMID:33357641 | PMC:PMC7772612 | DOI:10.1016/j.ihj.2020.09.016 (Source: Indian Heart J)
Source: Indian Heart J - December 28, 2020 Category: Cardiology Authors: Anil Ranjeetmal Jain Rakesh Kumar Aggarwal Nanyam Srinivas Rao Gauri Billa Shankar Kumar Source Type: research

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
CONCLUSION: Results support the use of sacubitril/valsartan in Indian patients with chronic HF with reduced ejection fraction with treatment benefits similar to global PARADIGM-HF cohort.PMID:33357641 | PMC:PMC7772612 | DOI:10.1016/j.ihj.2020.09.016 (Source: Indian Heart J)
Source: Indian Heart J - December 28, 2020 Category: Cardiology Authors: Anil Ranjeetmal Jain Rakesh Kumar Aggarwal Nanyam Srinivas Rao Gauri Billa Shankar Kumar Source Type: research

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
CONCLUSION: Results support the use of sacubitril/valsartan in Indian patients with chronic HF with reduced ejection fraction with treatment benefits similar to global PARADIGM-HF cohort.PMID:33357641 | PMC:PMC7772612 | DOI:10.1016/j.ihj.2020.09.016 (Source: Indian Heart J)
Source: Indian Heart J - December 28, 2020 Category: Cardiology Authors: Anil Ranjeetmal Jain Rakesh Kumar Aggarwal Nanyam Srinivas Rao Gauri Billa Shankar Kumar Source Type: research

OUTSTEP ‐HF: Randomised controlled trial comparing short‐term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction
ConclusionAfter 12  weeks of treatment, there was no significant benefit of sacubitril/valsartan on either 6MWT or in daytime physical activity measured by actigraphy compared with enalapril. (ClinicalTrials.gov number, NCT02900378). (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - December 14, 2020 Category: Cardiology Authors: Massimo F. Piepoli, Rizwan I. Hussain, Josep Comin ‐Colet, Ramon Dosantos, Philippe Ferber, Tiny Jaarsma, Frank Edelmann Tags: Research Article Source Type: research

Interaction of neutrophil counts and folic acid treatment on new-onset proteinuria in hypertensive patients.
Abstract We aimed to examine whether baseline neutrophil counts affected the risk of new-onset proteinuria in hypertensive patients, and, if so, whether folic acid treatment is particularly effective in proteinuria prevention in such a setting. A total of 8,208 eligible participants without proteinuria at baseline were analyzed from the renal sub-study of the China Stroke Primary Prevention Trial (CSPPT). Participants were randomized to receive a double-blind daily treatment of 10mg enalapril and 0.8mg folic acid (n=4,101) or 10mg enalapril alone (n=4,107). The primary outcome was new-onset proteinuria, defined as...
Source: The British Journal of Nutrition - December 14, 2020 Category: Nutrition Authors: Zhang Z, Liu M, Zhang Y, Zhou C, He P, Li H, Li J, Zhang Y, Liang M, Wang B, Xu X, Wang X, Huo Y, Hou FF, Nie J, Xu X, Qin X Tags: Br J Nutr Source Type: research

OUTSTEP ‐HF: Randomised controlled trial comparing short‐term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction
ConclusionAfter 12  weeks of treatment, there was no significant benefit of sacubitril/valsartan on either 6MWT or in daytime physical activity measured by actigraphy compared with enalapril. (ClinicalTrials.gov number, NCT02900378). (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - December 13, 2020 Category: Cardiology Authors: Massimo F. Piepoli, Rizwan I. Hussain, Josep Comin ‐Colet, Ramon Dosantos, Philippe Ferber, Tiny Jaarsma, Frank Edelmann Tags: Research Article Source Type: research

Heart failure in the last year: progress and perspective
AbstractResearch about heart failure (HF) has made major progress in the last years. We give here an update on the most recent findings. Landmark trials have established new treatments for HF with reduced ejection fraction. Sacubitril/valsartan was superior to enalapril in PARADIGM ‐HF trial, and its initiation during hospitalization for acute HF or early after discharge can now be considered. More recently, new therapeutic pathways have been developed. In the DAPA‐HF and EMPEROR‐Reduced trials, dapagliflozin and empagliflozin reduced the risk of the primary composite en dpoint, compared with placebo [hazard ratio (H...
Source: ESC Heart Failure - December 5, 2020 Category: Cardiology Authors: Daniela Tomasoni, Marianna Adamo, Markus S. Anker, Stephan Haehling, Andrew J. S. Coats, Marco Metra Tags: Review Source Type: research

Autophagy blockade mechanistically links proton pump inhibitors to worsened diabetic nephropathy and aborts the renoprotection of metformin/enalapril
Publication date: Available online 1 December 2020Source: Life SciencesAuthor(s): Dalia Kamal Mostafa, Mohamed Mostafa Khedr, Mervat Kamel Barakat, Amany Abdelbari Abdellatif, Amal Mohamed Elsharkawy (Source: Life Sciences)
Source: Life Sciences - December 3, 2020 Category: Biology Source Type: research

Molecules, Vol. 25, Pages 5605: Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein
Conclusion: Carnosine has promising inhibitory interactions with host ACE2 and nCoV spike protein and hence could offer a potential mitigating effect against the current COVID-19 pandemic. (Source: Molecules)
Source: Molecules - November 28, 2020 Category: Chemistry Authors: Saadah Deiab Al-Balas Basheti Tags: Article Source Type: research

Low ‐volume LC–MS/MS method for the pharmacokinetic investigation of carvedilol, enalapril and their metabolites in whole blood and plasma: Application to a paediatric clinical trial
Evidence ‐based pharmacotherapy for treatment of paediatric heart failure is lacking due to very limited pharmacokinetic data. Therefore, a low‐volume LC–MS/MS assay was developed, validated and applied to determine enalapril, carvedilol and their metabolites using whole blood or plasma. The establishe d assay enables to generate reliable data of maturation‐dependent metabolism of the drugs and contributes to the implementation of evidence‐based pharmacotherapy in this vulnerable collective. AbstractEvidence ‐based pharmacotherapy with carvedilol and enalapril in children suffering from heart failure is ins...
Source: Drug Testing and Analysis - November 23, 2020 Category: Drugs & Pharmacology Authors: Tanja Gangnus, Bjoern B. Burckhardt, CARS consortium Tags: RESEARCH ARTICLE Source Type: research

Oxidative Stress in Graves Disease and Graves Orbitopathy
Oxidative stress is involved in the pathogenesis of Graves hyperthyroidism (GH) and Graves orbitopathy (GO) and an antioxidant approach has been proposed for both. In GH, a disbalance of the cell redox state is associated with thyroid hyperfunction and antithyroid medications may reduce oxidative stress. Tissue hypoxia participates in the pathogenesis of GO, and oxygen free radicals are involved in the typical changes of orbital tissues as reported by in vitro and clinical studies. Antioxidant agents, especially selenium, have been proposed as a therapeutic option for GH and GO. A clinical study regarding the use of seleni...
Source: European Thyroid Journal - November 20, 2020 Category: Endocrinology Source Type: research

[ASAP] Simulation and Assignment of the Terahertz Vibrational Spectra of Enalapril Maleate Cocrystal Polymorphs
The Journal of Physical Chemistry ADOI: 10.1021/acs.jpca.0c08093 (Source: Journal of Physical Chemistry A)
Source: Journal of Physical Chemistry A - November 13, 2020 Category: Chemistry Authors: Margaret P. Davis, Mizuki Mohara, Kei Shimura, and Timothy M. Korter Source Type: research

Traditional Chinese Medicine Formulation Huangqi Jianzhong Tang Improves Cardiac Function after Myocardial Infarction in Rats.
Authors: Bao YR, Jiang WY, Yu JY, Chen JW, Zhang GX Abstract Huangqi Jianzhong Tang (HQJZT) is a traditional Chinese herbal formula consisting of seven different herbs: Radix Astragali, Radix Paeoniae Alba, Ramulus Cinnamomi, Fructus Jujubae, Glycyrrhizae Radix Et Rhizoma Praeparata Cum Melle, Rhizoma Zingiberis Recens, and Saccharum Granorum. The present study aims to evaluate the possible effects of HQJZT on cardiac function in acute myocardial infarction (AMI) and related mechanism. AMI model was established by ligation of the left anterior descending coronary artery followed by one-week HQJZT treatment. Surviva...
Source: Evidence-based Complementary and Alternative Medicine - November 6, 2020 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
CONCLUSION: Results support the use of sacubitril/valsartan in Indian patients with chronic HF with reduced ejection fraction with treatment benefits similar to global PARADIGM-HF cohort. PMID: 33357641 [PubMed - in process] (Source: Indian Heart J)
Source: Indian Heart J - November 1, 2020 Category: Cardiology Authors: Jain AR, Aggarwal RK, Rao NS, Billa G, Kumar S Tags: Indian Heart J Source Type: research

A case of Ramsay Hunt syndrome that began with vestibular symptoms: A great mimicker
An 83-year-old woman presented to the emergency department with a 2-day history of persistent vertigo. She also complained of neck pain, lightheadedness, nausea, and vomiting. She had hypertension and had undergone balloon angioplasty for stable angina pectoris 1 month prior. Her medications included enalapril, bisoprolol, aspirin, prasugrel, rosuvastatin, and torsemide. Physical examination revealed that she was afebrile, alert, and oriented. Her gait was wobbly and deviated toward the right. Direction-fixed horizontal nystagmus beating toward the left was noted. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - October 31, 2020 Category: General Medicine Authors: Masashi Yokose, Taro Shimizu Tags: Clinical Communication to the Editor Source Type: research

Low ‐volume LC‐MS/MS method for the pharmacokinetic investigation of carvedilol, enalapril and their metabolites in whole blood and plasma: application to a paediatric clinical trial
AbstractEvidence ‐based pharmacotherapy with carvedilol and enalapril in children suffering from heart failure is insufficient owing to limited pharmacokinetic data.1 While a few datasets regarding enalapril, its metabolite enalaprilat and carvedilol in children have been published, pharmacokinetic data on carvedilol metabolites is missing. However, for both drug substances, their active metabolites contribute substantially to drug efficacy. As data can hardly be derived from adults owing to the unknown impacts of enzymatic maturation and ontogeny during childhood, customised assays are important to facilitate paediatric...
Source: Drug Testing and Analysis - October 30, 2020 Category: Drugs & Pharmacology Authors: Tanja Gangnus, Bjoern B. Burckhardt, on behalf of the CARS consortium, Michiel Dalinghaus, Marijke H. Meulen, Gideon J. Marchie Sarvaas, Nico A. Blom, Arend D.J. Harkel, Hans M.P.J. Breur, Lukas A.J. Rammeloo, Ronald Tanke Tags: RESEARCH ARTICLE Source Type: research

Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM ‐HF
ConclusionsPatients with longer ‐duration HF had more co‐morbidity, worse quality of life, and higher rates of HF hospitalization and death. The benefit of a neprilysin inhibitor was consistent, irrespective of HF duration. Switching to sacubitril/valsartan had substantial benefits, even in patients with long‐standing HF. (Source: ESC Heart Failure)
Source: ESC Heart Failure - October 19, 2020 Category: Cardiology Authors: Su E. Yeoh, Pooja Dewan, Akshay S. Desai, Scott D. Solomon, Jean L. Rouleau, Marty Lefkowitz, Adel Rizkala, Karl Swedberg, Michael R. Zile, Pardeep S. Jhund, Milton Packer, John J.V. McMurray Tags: Original Research Article Source Type: research

Enalapril improves obesity associated liver injury ameliorating systemic metabolic markers by modulating Angiotensin Converting Enzymes ACE/ACE2 expression in high-fat feed mice
Publication date: Available online 10 October 2020Source: Prostaglandins & Other Lipid MediatorsAuthor(s): Daniel Silva Moraes, Deborah de Farias Lelis, João Marcus Oliveira Andrade, Lara Meyer, André Luiz Sena Guimarães, Alfredo Maurício Batista De Paula, Lucyana Conceição Farias, Sérgio Henrique Sousa Santos (Source: Prostaglandins and Other Lipid Mediators)
Source: Prostaglandins and Other Lipid Mediators - October 11, 2020 Category: Lipidology Source Type: research

Therapeutic effects of various renin angiotensin modulators on hyperglycemia-induced cataract formation in Sprague Dawley rats.
CONCLUSION: Overall, our findings suggest that topical treatment with renin angiotensin modulators delayed the onset of diabetes-induced cataract formation. PMID: 33016125 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - October 3, 2020 Category: Opthalmology Authors: Shree J, Choudhary R, Bodakhe SH Tags: Eur J Ophthalmol Source Type: research

Angiotensin inhibition and cellular senescence in the developing rat kidney.
In this study, we aimed to investigate the effect of renin angiotensin system (RAS) blockade on renal cell senescence in the developing rat kidney. Newborn rat pups were treated with enalapril (30 mg/kg/day) or vehicle for seven days after birth. We investigated the intrarenal expressions of cell cycle regulators p21 and p16 with immunoblots and immunohistochemistry at postnatal day 8. For the determination of renal cellular senescence, immunostaining for senescence-associated β-galactosidase (SA-β-gal) and telomerase reverse transcriptase (TERT) was also performed. Enalapril treatment showed significant altera...
Source: Experimental and Molecular Pathology - September 29, 2020 Category: Pathology Authors: Yoo KH, Yim HE, Bae ES Tags: Exp Mol Pathol Source Type: research

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
Publication date: Available online 28 September 2020Source: Indian Heart JournalAuthor(s): Anil Ranjeetmal Jain, Rakesh Kumar Aggarwal, Srinivas Rao Nanyam, Gauri Billa, Shankar Kumar (Source: Indian Heart Journal)
Source: Indian Heart Journal - September 29, 2020 Category: Cardiology Source Type: research

The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure
ConclusionsIn AWAKE-HF, no detectable differences in activity and sleep were observed when comparing sacubitril/valsartan with enalapril in patients with HFrEF using a wearable biosensor.Clinical trial registrationClinicalTrials.gov, NCT02970669. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - September 25, 2020 Category: Cardiology Source Type: research

Osimertinib induced cardiomyopathy: A case report
Rationale: Cardiotoxicity related to osimertinib, including cardiac failure, QT prolongation, and atrial fibrillation, has been reported as an extremely rare incidence in patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the occurrence of osimertinib-induced cardiomyopathy. Patient concerns: A 76-year old woman was treated with afatinib (40 mg/day) as the 1st line treatment due to recurrence after surgical resection for pulmonary adenocarcinoma. However, she experienced recurrence with positive T790 M, and osimertinib (80 mg/day) was administered as the 2nd line therapy. ...
Source: Medicine - September 25, 2020 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Efficacy and safety of sacubitril ‐valsartan in heart failure: a meta‐analysis of randomized controlled trials
AbstractAimsSacubitril ‐valsartan has been shown to have superior effects over angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure (HF) and hypertension. The efficacy and safety of sacubitril‐valsartan in patients with HF are controversial. We performed a meta‐ analysis of randomized controlled trials to assess and compare the effect and adverse events of sacubitril‐valsartan, valsartan, and enalapril in patients with HF.Methods and resultsWe conducted a systematic search using PubMed, Embase, the Cochrane Library, andClinicalTrials.gov. Randomized controlled ...
Source: ESC Heart Failure - September 24, 2020 Category: Cardiology Authors: Hongzhou Zhang, Tieqiu Huang, Wen Shen, Xiuxiu Xu, Pingping Yang, Dan Zhu, Haiyang Fang, Hongbing Wan, Tao Wu, Yanqing Wu, Qinghua Wu Tags: Original Research Article Source Type: research